Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAE1 | Q13564 | 12/20 | 0.47 |
| ▸ | UBA3 | Q8TBC4 | 12/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23456099 | 1.00 | NAE1 (0.47) | NAE1UBA3EGFRERBB3SMN1; SMN2 | |
| SCHEMBL27250614 | 0.91 | EGFR (0.49) | NAE1UBA3EGFRERBB3SMN1; SMN2 | |
| SCHEMBL23456000 | 0.84 | EGFR (0.41) | NAE1UBA3EGFRERBB3SMN1; SMN2 | |
| SCHEMBL27252043 | 0.84 | EGFR (0.47) | EGFRERBB3SMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL27250616 | 0.82 | EGFR (0.49) | NAE1UBA3EGFRERBB3SMN1; SMN2 | |
| SCHEMBL30960669 | 0.81 | EGFR (0.48) | NAE1UBA3EGFRERBB3ADORA3 | |
| SCHEMBL23456613 | 0.81 | EGFR (0.48) | NAE1UBA3EGFRERBB3ADORA3 | |
| SCHEMBL23456082 | 0.80 | NAE1 (0.46) | NAE1UBA3EGFRERBB3SMN1; SMN2 | |
| SCHEMBL27250613 | 0.78 | EGFR (0.45) | NAE1UBA3EGFRERBB3SMN1; SMN2 | |
| SCHEMBL14719969 | 0.75 | NAE1 (0.47) | NAE1UBA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-27 | — | — | US | disclosed |
| US-11542293-B2 | Sting modulator compounds, and methods of making and using | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542293-B2 | Sting modulator compounds, and methods of making and using | STING1, CGAS, MAVS | NAE1 1571/4885UBA3 2354/4885EGFR 1818/4885 |
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | STING1, CGAS, MAVS | NAE1 1571/4885UBA3 2354/4885EGFR 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.